<DOC>
	<DOCNO>NCT00022763</DOCNO>
	<brief_summary>This study evaluate T-20 child .</brief_summary>
	<brief_title>T-20 Plus Selected Anti-HIV Treatment HIV-Infected Children Adolescents</brief_title>
	<detailed_description>Children stratify age group ( 3 11 year 12 16 year ) . Samples HIV-1 genotype phenotype resistance test obtain screen aid selection concomitant antiretrovirals . Simultaneous initiate T-20 , patient begin `` new '' optimize antiretroviral regimen base patient ' prior treatment history , historical resistance test result , result test performed screening . Patients follow safety assessment Weeks 1 , 2 , 4 , monthly Week 24 bimonthly Week 48 . Pharmacokinetic sampling select study visit perform .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are 3 16 year age consent parent guardian . Have viral load least 5000 copies/ml . Have take least 2 3 licensed antiHIV drug class least 3 month . Have stable therapy least 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>pentafuside</keyword>
</DOC>